The list includes not just the drug names but also other information like treatment, ingredients, and the disease they cure, which could help them (you) easily choose the drug most profitable to develop a generic version.
Without any delay, here is the list of drugs.
The article has a list of drug patents in 2030. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Drug Patent Expiration Report
Download the Drug Expiration Report 2026-2030 in pdf:
Tafinlar
Dabrafenib
| Patents | Expiration Date |
|---|---|
| US7994185 | January 20, 2030 |
| US8415345 | January 20, 2030 |
| US8703781 | October 15, 2030 |
Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: DABRAFENIB MESYLATE
Treatment: Braf (v600)-mutated Metastatic Melanoma
Copiktra
Duvelisib
| Patents | Expiration Date |
|---|---|
| US8193182 | February 13, 2030 |
| USRE46621 | May 17, 2032 |
Dosage: Oral
Company: Secura Bio Inc
Ingredients: DUVELISIB
Treatment: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Follicular Lymphoma
Seglentis
Celecoxib/Tramadol
| Patents | Expiration Date |
|---|---|
| US10238668 | April 19, 2030 |
| US9012440 | April 19, 2030 |
| US8598152 | April 19, 2030 |
| US10245276 | April 19, 2030 |
Dosage: Oral
Company: Kowa Pharmaceuticals America Inc
Ingredients: CELECOXIB; TRAMADOL HYDROCHLORIDE
Treatment: Management And Treatment Of Pain
Veltassa
Patiromer
| Patents | Expiration Date |
|---|---|
| US8337824 | May 29, 2030 |
Dosage: Oral
Company: Vifor Pharma Inc
Ingredients: PATIROMER SORBITEX CALCIUM
Treatment: High Blood Potassium
Olumiant
Baricitinib
| Patents | Expiration Date |
|---|---|
| US8158616 | June 8, 2030 |
Dosage: Oral
Company: Eli Lilly And Co
Ingredients: BARICITINIB
Treatment: Rheumatoid Arthritis And Covid-19
Voxzogo
Vosoritide
| Patents | Expiration Date |
|---|---|
| US8198242 | June 11, 2030 |
Dosage: Subcutaneous
Company: Biomarin Pharmaceutical Inc
Ingredients: VOSORITIDE
Treatment: Achondroplasia
Apadaz
Acetaminophen/Benzhydrocodone
| Patents | Expiration Date |
|---|---|
| US9132125 | July 1, 2030 |
| US9549923 | July 1, 2030 |
| US8748413 | July 10, 2030 |
| US8461137 | February 22, 2031 |
Dosage: Subcutaneous
Company: Kvk Tech Inc
Ingredients: ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE
Treatment: Moderate To Severe Pain
Segluromet
Ertugliflozin-Metformin
| Patents | Expiration Date |
|---|---|
| US8080580 | July 13, 2030 |
Dosage: Subcutaneous
Company: Merck Sharp And Dohme Corp
Ingredients: ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes
Qinlock
Ripretinib
| Patents | Expiration Date |
|---|---|
| US8188113 | July 27, 2030 |
| US8461179 | June 7, 2032 |
Dosage: Oral
Company: Deciphera Pharmaceuticals Llc
Ingredients: RIPRETINIB
Treatment: Advanced Gastrointestinal Stromal Tumor
Parsabiv
Etelcalcetide
| Patents | Expiration Date |
|---|---|
| US9701712 | July 29, 2030 |
| US9278995 | July 29, 2030 |
| US8377880 | July 29, 2030 |
| US8999932 | February 7, 2031 |
Dosage: Intravenous
Company: Kai Pharmaceuticals Inc
Ingredients: ETELCALCETIDE
Treatment: Secondary Hyperparathyroidism
Alunbrig
Brigatinib
| Patents | Expiration Date |
|---|---|
| US9012462 | July 31, 2030 |
| US10385078 | November 10, 2035 |
Dosage: Oral
Company: Takeda Pharmaceuticals USA Inc
Ingredients: BRIGATINIB
Treatment: Non Small Cell Lung Cancer
Brexafemme
Ibrexafungerp
| Patents | Expiration Date |
|---|---|
| US8188085 | August 28, 2030 |
| US10174074 | January 19, 2035 |
| US10927142 | January 19, 2035 |
Dosage: Oral
Company: Scynexis Inc
Ingredients: IBREXAFUNGERP CITRATE
Treatment: Vulvovaginal Candidiasis (VVC)
Nubeqa
Darolutamide
| Patents | Expiration Date |
|---|---|
| US8975254 | October 27, 2030 |
| US9657003 | October 27, 2030 |
| US11046713 | October 27, 2030 |
| US10711013 | October 27, 2030 |
| US10383853 | January 28, 2036 |
| US10010530 | January 28, 2036 |
| US11168058 | February 27, 2038 |
Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: DAROLUTAMIDE
Treatment: Non-metastatic Castration-resistant Prostate Cancer
Harvoni/Hepcinat-LP
Ledipasvir/Sofosbuvir
| Patents | Expiration Date |
|---|---|
| US8822430 | November 12, 2030 |
| US8088368 | November 12, 2030 |
| US10039779 | July 30, 2034 |
Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: LEDIPASVIR; SOFOSBUVIR
Treatment: Hepatitis C
Rinvoq
Upadacitinib
| Patents | Expiration Date |
|---|---|
| USRE47221 | December 1, 2030 |
| US8962629 | January 15, 2031 |
| US10981923 | October 17, 2036 |
| US9951080 | October 17, 2036 |
| US11186584 | October 17, 2036 |
Dosage: Oral
Company: Abbvie Inc
Ingredients: UPADACITINIB
Treatment: Rheumatoid Arthritis and Psoriatic Arthritis
Nerlynx
Neratinib
| Patents | Expiration Date |
|---|---|
| US7399865 | December 29, 2030 |
Dosage: Oral
Company: Puma Biotechnology Inc
Ingredients: NERATINIB MALEATE
Treatment: Breast Cancer
Conclusion
As we look ahead to 2030, the pharmaceutical landscape is poised for significant changes with the expiration of patents on several key medications. This upcoming wave of patent expirations presents opportunities for generic drug manufacturers, potentially leading to increased competition and more affordable treatment options for patients.
For those interested in exploring patent expiration dates beyond the drugs listed in this article, GreyB offers a valuable resource: Pharsight. This platform provides comprehensive information on approved drug products, including their patent and exclusivity data. Users can search by drug name, active ingredient, or application number to find specific patent expiration dates.
